Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03239340 · ClinicalTrials.gov registry record · Phase 2
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT03239340 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 154 participants.
The verdict
NCT03239340, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.
Interventions
- DRUG Osimertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2023-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03239340
The ClinicalTrials.gov registry entry for NCT03239340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Osimertinib is the first listed.
NCT03239340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03239340 about?
NCT03239340 is a clinical study titled "A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib". A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.
What is the current status of trial NCT03239340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2018-05-30. Estimated completion is 2023-09-19.
What interventions are being tested in trial NCT03239340?
The interventions under investigation include: Osimertinib (DRUG).
Who is sponsoring clinical trial NCT03239340?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.